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Abstract
Humans evolved in a world with high levels of infection resulting in high mortality across the life
span and few survivors to advanced ages. Under such conditions, a strong acute-phase inflammatory
response was required for survival; however, inflammatory responses can also promote chronic
diseases of aging. We hypothesize that global historical increases in life span at older ages are partly
explained by reduced lifetime exposure to infection and subsequent inflammation. To begin a test of
this hypothesis, we compare C-reactive protein (CRP); levels in two populations with different
epidemiological environments: the Tsimane of Bolivia and persons in the United States. High CRP
is significantly more prevalent among the Tsimane up through middle age; by age 35, the Tsimane
have spent more years with high CRP than have Americans at age 55. Further testing of the links
among infection, inflammation, and chronic diseases of aging among the Tsimane requires collection
of age-specific indicators of atherosclerosis and cardiac function.
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Explanations of increases in life expectancy at older ages often focus on the role of relatively
recent medical advances and behavioral changes. The historical reduction of infections is
recognized as a major factor in the decline of early age mortality in the past two centuries: We
and others have noted that cohorts who experienced lower mortality when young also
experienced reduced mortality among survivors in old age (1–4). It is further hypothesized that
population levels of inflammation have decreased over time in parallel with the reduction in
mortality from infectious diseases (1,2). A reduction in the prevalence and duration of time
spent with infectious conditions should lower the levels of lifetime inflammation. Because
chronically elevated blood levels of inflammatory cells and proteins are independent factors
in the atherosclerotic process, reductions in lifetime levels of inflammation should slow
deterioration in the cardiovascular system with aging, as well as delay the onset of chronic
cardiovascular diseases of old age (5–9). Cohort reductions in inflammation should result in
increased ages at mortality, heart attack, stroke, and cognitive loss (8,9). The hypothesis that
lifetime inflammation has decreased in modern populations and that aging processes are
consequently delayed relative to historical populations cannot be directly tested because of the
lack of tissue samples from these earlier eras. As an approach to testing the inflammation–
aging hypothesis in modern populations, we compare C-reactive protein (CRP) levels in two
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populations with different epidemiological environments: the Tsimane of the Bolivian Amazon
versus Americans.
Methods
Lacking statistically valid blood or tissue samples from historical populations, we sought a
contemporary population that had limited exposure to modern medicine with a high level of
mortality that would provide a useful calibration for understanding past populations and
modern epidemiologic transitions. The Tsimane are indigenous foragers in the Bolivian
Amazon with limited access to modern medicine, low life expectancy, and high mortality from
infection. We examined CRP, a serum marker of inflammation, across the age range in this
population for comparison with age-specific CRP and mortality levels in the United States.
These two populations represent extremes in contemporary levels of infectious mortality,
exposure to inflammation, and life expectancy.
In July 2002, Kaplan and Gurven initiated long-term research on Tsimane life history. Data
were collected on demographic, economic, social, and health characteristics of >2200 Tsimane
living in 17 study villages (9). These forager-horticulturalists live in about 60 small villages
of extended family clusters located in a forested lowland tropical area. Despite their exposure
to Jesuit missionaries in the late 17th century, the Tsimane were never successfully settled in
missions and are relatively unacculturated. Their isolation will not last much longer because
of increasing access to market towns, especially as supplies of forest game and fish diminish
with increased encroachment by loggers and colonists. The life history data provide the basis
for estimating life expectancy over the past 15 years in this population (10).
Inflammation is indicated in both countries by levels of serum CRP. Elevation of CRP is an
acute phase response to infection that mediates bacterial clearance and is widely used to indicate
systemic inflammation. However, chronic exposure to even moderately high CRP is associated
with increased risk of cardiovascular events and other disabilities of aging in long-lived
populations (9,11). We examined age-specific prevalence of high CRP and estimated the
average number of years spent with high CRP for survivors up to specified ages.
For the Tsimane, CRP was assayed in whole blood collected by venipuncture from 607 people
over the age of 4 during medical examinations in four villages during the summers of 2004
and 2005. Whole blood was hand-centrifuged on site at an ambient temperature and then frozen
and stored in liquid nitrogen pending transport to the United States for assay. Assays were done
using the Immulite 2000, high-sensitivity CRP assay, a solid-phase, chemiluminescent
immunometric assay with a mean replicate coefficient of variation of 5.6% (Diagnostics
Products Corporation, Siemens, Deerfield, IL). An indication of the reliability of this assay is
that the percentages of high serum CRP reported for Tsimane children resemble those reported
for Tsimane children of the same age from assays of dried blood spots after using the conversion
formula (12).
The U.S. data on CRP are from the National Health and Examination Study (NHANES); 1999–
2002, a nationally representative sample from noninstitutionalized persons collected from 1999
through 2002. Values of serum CRP were determined from samples analyzed by high-
sensitivity latex-enhanced nephelometry on a BN II Nephelometer (Dade Behring, Siemens)
(13). The assay used monoclonal anti-CRP antibodies and a calibrator that was traceable to the
World Health Organization (WHO) reference material. The mean replicate coefficient of
variation for the assay is 6.4% (13). Values of CRP for the Tsimane based on the Immulite
2000 assay were standardized to the Dade Behring assay used in NHANES (14).
This analysis defined CRP > 3.0 mg/L as the cutoff for high CRP, which indicates high
cardiovascular risk (15). Because we are interested in lifetime exposure to high inflammation,
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we use the age-specific prevalence of high CRP to estimate the number of years lived with
high CRP by specified ages for both the Tsimane and U.S. data. The calculation assumes that
the prevalence of high CRP observed in an age interval represents the proportion of life lived
with high CRP for persons who survive through the interval. We also assume that the
prevalence of high CRP below the age of measurement (4 years for the Tsimane and 2 years
for the Americans) is equal to that in the 5–9 age range.
Results
A Tsimane life table was constructed by Gurven from recent interviews representing the period
from 1950–1989 (29,464 person-years of life) (10). Recent life expectancy, 42.8 years, is very
close to that in 19th century Western Europe, for example, Sweden in 1843 (42.6 years) (Figure
1). In contrast to the Tsimane, the current U.S. life expectancy is almost twice as high (77.2
years) with infections responsible for only a small percentage of deaths.
The age-specific proportions with serum CRP > 3.0 mg/L differ strikingly between the U.S.
and Tsimane data (Figure 2). The Tsimane have significantly higher age-specific proportions
with high serum CRP up to age 45–54 years than do the Americans. The proportion with high
CRP among young Tsimane adults exceeds U.S. values for ages 65 and older. These remarkable
elevations of CRP can be attributed to endemic infections in the Tsimane, as documented above.
Few U.S. children have high CRP at any time relative to the Tsimane because childhood
infections are less prevalent in the United States. Nonetheless, in both samples, the percentage
with high CRP increases after childhood. Factors associated with chronically high CRP in low-
mortality countries include obesity, smoking, and the onset of cardiovascular conditions and
other chronic degenerative diseases of aging (16,17). At the older ages, the Tsimane and U.S.
populations have similar serum CRP.
Lifetime exposure to high levels of CRP is implicated in the development of atherosclerosis.
Longer exposure to high inflammation early in life results in the Tsimane having lived more
years with high inflammation by the time they reach adulthood. Years lived with high
inflammation estimated from the prevalence is shown in Figure 3 and Table 1. By age 15, the
average Tsimane has lived 6.1 years with high CRP, whereas the average time with high CRP
for an American 15-year-old is only 1.5 years. By age 35, the Tsimane have spent more years
with high CRP than have Americans at age 55. Over their entire life history up to age 70, the
Tsimane spend more years and a greater proportion of life with high CRP than do people in
the United States.
Discussion and Conclusion
The Tsimane population provides a unique opportunity to evaluate the role of CRP in an
epidemiologic setting with current mortality as high as that in 19th century Europe. The
similarity of the levels and the age-specific pattern of mortality for the Tsimane and Swedish
suggests that both the Tsimane and those living in Northern Europe 150 years ago suffered
from high levels of infectious mortality and morbidity (18,19). Medical examinations of 2800
Tsimane in 2004 and 2005 document the high levels of endemic parasitism and infection. More
than two thirds (69%); were infected with at least one species of intestinal parasite at the time
of the examination, and >60% had symptoms of either a gastrointestinal or respiratory illness.
Our evidence shows that persons in a high-mortality, highly infectious environment have
higher CRP in the first four decades of life than persons in a low-mortality, low-infection
environment have. Based on the association of CRP elevations with future cardiovascular
events in populations with lower mortality and infections, we hypothesize that premature
cardiovascular disease is a factor in the higher adult mortality of Tsimane. Studies of young
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persons in the United States have linked high CRP to vascular deterioration beginning in
childhood (20,21). In the United States and other generally healthy populations, individual
exposure to common infections has been associated with both CRP levels and risk of
cardiovascular events (6). Thus, the greater exposure of Tsimane to inflammation could
promote earlier vascular disease and other dysfunctions of aging. Conversely, the reductions
in inflammatory exposure in countries like the United States may have been a significant factor
in delaying aging and mortality in the past.
It is not straightforward to compare levels of CRP among the Tsimane to those in other
populations. Most reports on CRP in populations come from those with low mortality and of
European extraction; most do not show an age pattern of change in CRP, but report on one age
group or do not differentiate by age. However, growing evidence suggests that CRP levels vary
widely around the world. Tsimane children have higher levels of CRP than children in Kenya
and Samoa; this finding would be consistent with relative levels of infection (12). Tsimane
adults also have higher CRP than adults in the indigenous North Asian Yakut population, a
group with relatively high, but recently decreasing, life expectancy due to rapid social change
in the area that was once the Soviet Union (22). In fact, CRP levels among the Yakut are almost
as low as levels in Japan which has much lower levels of CRP than the United States, the U.K.,
and Germany (22,23). In contrast, Tsimane adults 45 years old and older have a median CRP
level (3.0 mg/L) close to that of the adult American Indian population (3.2 mg/L), with low
levels of infection but high levels of diabetes and other cardiovascular risk factors (24).
In populations with low levels of infection and mortality, high inflammation has been strongly
implicated in the pathophysiology of arterial degeneration and immunosenescence, as well as
in a wide variety of chronic diseases including diabetes (25), metabolic syndrome (26),
congestive heart failure (27), Alzheimer’s disease (28,29), and disability (30). These links
between inflammation and most major health problems support the hypothesis that
inflammation is a common mechanism of many degenerative conditions linked to aging (28,
31,32). There are many links between life circumstances and inflammation in addition to the
infection emphasized among the Tsimane: The importance of various paths depends on the
population circumstances. Currently, in the United States, levels of inflammation among
children and young adults are predicted by weight and obesity, exposure to cigarette smoke,
and air pollution (33).
Further testing of our hypothesis requires new information on the role of arterial disease in
adult mortality among the Tsimane. We must also test competing hypotheses about mortality
from immune dysfunctions caused by high levels of lifetime infection and inflammation. CRP,
for example, can impair the differentiation of antigen-presenting monocytes (dendritic cells)
(34). While the Tsimane are rapidly gaining access to medicine and immunizations, we may
be able to glean critical insights about the nature of mortality in a highly infectious environment
that will more fully explain the doubling of life expectancy during the last 200 years and the
potential for further increases in many parts of the world. In addition, a link between
inflammation and late life health would provide evidence of antagonistic pleiotropy, that is, a
process that enhances survival and reproductive success in the young, but with delayed adverse
consequences at older ages (6,28).
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Probability of dying among Tsimane (1950–1989), Swedes (1843), and Americans (2001).
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Prevalence of high-risk C-reactive protein (CRP) (>3 mg/L) in Tsimane and Americans.
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Years lived with high C-reactive protein (CRP) for those who survive to a specified age.
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Table 1
Years Lived with High C-Reactive Protein (CRP) for Those Who Survive to Specified Age; Proportion of Life
Lived With High CRP Up to Specified Age
Age
Tsimane United States
Years With High CRP
Proportion of Life Lived With High
CRP Years With High CRP
Proportion of Life Lived With High
CRP
10 3.6 0.36 1.0 0.10
15 6.1 0.41 1.5 0.10
25 10.3 0.41 3.5 0.14
35 15.0 0.43 6.8 0.19
55 24.5 0.45 14.1 0.26
65 30.1 0.46 18.8 0.29
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